VTGN - רווח נקי למניה (EPS TTM) vistagen.com

The prospects for Vistagen Therapeutics (VTGN) depend on FDA approval and the commercialization of nasal sprays for anxiety. The 12-month rolling earnings per share history displayed on GURU.Markets confirms the resilience of the model, where -1.40 represents the latest metric reading. Growth is driven by IT platforms for the automation of compound bioscreening and high loyalty among volunteers in clinical trials for innovative psychotropic agents.
פילוחי מדדים פיננסיים ומדדי שוק עבור vistagen.com (VTGN)

Net income per share over 12 months reflects the portion of total income attributable to a single security after deducting all expenses for Vistagen Therapeutics (VTGN). This metric measures the actual efficiency of the business's capitalization. By analyzing the one-year net income per share trend, an investor can see the impact of costs related to automated drug synthesis and psychiatrist compensation. The price action of the line confirms the company's ability to convert biopharmaceutical developments into profit. The stability of this value determines the long-term financial sustainability of the issuer.